Nordicus Partners Business Summary

Nordicus Partners Corp (NORD) operates as a specialized business accelerator and holding company designed to bridge Nordic life sciences innovation with the United States capital markets and regulatory landscape. The company generates revenue through a dual-stream model: providing high-level corporate finance advisory services—including capital raising, strategic market development, and M&A facilitation—and acquiring majority equity stakes in high-potential biotech subsidiaries to drive value through clinical progression and eventual exits. Its primary business segments are concentrated in life sciences development, specifically targeting unmet medical needs in oral health and dermatology through its wholly-owned subsidiaries Orocidin A/S, Bio-Convert A/S, and the newly formed NoviThera ApS. Within the micro-cap financial and life sciences consulting sector, Nordicus competes with firms such as AMTD IDEA Group, Siebert Financial, and Dominari Holdings, positioning itself as a niche, cross-border specialist that combines Nordic R&D with American operational expertise. The leadership team is anchored by Chief Executive Officer Henrik Rouf, an international financier with over 30 years of experience in merchant banking and fund management, and Chief Financial Officer Bennett J. Yankowitz, who brings extensive legal and financial structuring expertise to the board. The company’s strategic direction is further guided by Chairman Peter Severin, a veteran of the pharmaceutical industry with previous leadership roles at Novartis and AstraZeneca. The Board of Directors was recently expanded to include Andrew J. Ritter, the founder and former CEO of Ritter Pharmaceuticals, and Kim T. Mücke, a former partner at Deloitte Denmark with deep expertise in financial reporting and risk management. Notable institutional backing and significant insider ownership come from major shareholders such as GK Partners ApS and AC Nordic, the latter led by board member and finance veteran Torben Jensen.